SCRIPT team present poster at ASME Midlands Medical Education Conference

10th April 2024

In April, the SCRIPT team was invited to present a poster at the 8th Association for the Study of Medical Education (ASME) Midlands Medical Education Conference in Birmingham. The poster showcased a systematic review assessing the think aloud technique (a process involving the verbalisation of conscious thoughts) as a method to improve understanding of the decision-making process behind prescribing. SCRIPT research associate Daniel discussed the findings with medical educators from other Midlands Universities, as a new avenue for research. 

Reference: 

MARTIN, D., COLEMAN J & PONTEFRACT, S. 2024. The effectiveness of think aloud technique to map decision making processes for prescribing: a systematic review. 8th ASME Midlands Medical Education Conference. University of Birmingham, Medical School, UK. (Poster presentation). 

More News

SCRIPT eLearning Shortlisted for Prestigious HSJ Patient Safety Award

SCRIPT eLearning is delighted to announce that it has been shortlisted in the ‘Patient Safety Education and Training’ category of the HSJ Patient Safety Awards 2026, recognising its ongoing contribution to improving safety in prescribing and medicines management. The...

Birmingham Education for Health Professional Conference 2026

The SCRIPT team was delighted to present a poster at the Birmingham Education for Health Professional Conference 2026, led by our Research Associate Divya Singh. The poster, titled "eLearning in Multidisciplinary Prescribing Education: A Longitudinal Evaluation...

New Modules Under Development

We are committed to developing and adding new modules to ensure the SCRIPT programme continues to reflect current clinical practice and meets our learners’ changing needs. We have several modules at various stages of development, including Drugs of Addiction and...

Updated module – Diabetes: Antihyperglycaemic Medicines

NICE has recently updated its guidance on ‘Type 2 diabetes in adults: management’. In a change to national guidance modified‑release metformin alongside an SGLT2 inhibitor is now recommended as first‑line treatment for adults with type 2 diabetes mellitus....